08:01 AM EDT, 09/18/2024 (MT Newswires) -- GSK (GSK) said Wednesday that the phase 3 trial evaluating the co-administration of AREXVY with SHINGRIX in adults aged 50 years and older met its primary endpoint.

The data showed a non-inferior immune response when both vaccines were co-administered compared with a separate administration, the company said.

The company further said the co-administration was well tolerated, with acceptable reactogenicity and safety profiles. The most frequently reported adverse events were pain at the injection site, fatigue, and myalgia.

The company plans to submit results from the trial for peer-reviewed scientific publication and to support regulatory submissions to the US Food and Drug Administration and other regulators.

SHINGRIX is approved for the prevention of shingles, while AREXVY is approved for the prevention of lower respiratory tract disease caused by respiratory syncytial virus.

Price: 42.55, Change: -0.01, Percent Change: -0.02